High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)
Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_61
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Wiley